Codexis

At the Cantor Fitzgerald conference, Codexis presented its ECO‑Synthesis platform for enzymatic siRNA manufacture as a capital‑ and solvent‑sparing alternative to solid‑phase organosynthesis, citing roughly 70% higher capital efficiency. Its innovation lab routinely produces 100 grams, plans 500 grams by late 2024/early 2025, and aims for kilogram‑scale production by the end of 2027. The company highlighted technical advances such as stereochemical control and initiation from a single nucleotide, and said it is in ongoing dialogue with the FDA on product specifications and comparability. Codexis is targeting CDMO partnerships, collaborations with pharmaceutical companies and licensing to address siRNA industry scaling bottlenecks. » Altro su de.investing.com

Codexis reported Q1 2026 EPS of -0.10 (expectation -0.16) and revenue of $15.2 million versus $14.79 million expected. Revenue rose 102.7% year over year, mainly due to a technology transfer agreement with Merck; product gross margin improved to 71%. Operating expenses were reduced, net loss narrowed significantly, and cash reserves are expected to fund the business through the end of 2027. For Q2 the company expects around $16.5 million in revenue; the stock rose about 1.5% in after-hours trading. » Altro su de.investing.com

Codexis reported Q4 2025 EPS of 0.11 USD (expectation -0.04 USD) and revenue of 38.92 million USD, up 81% year-on-year. A technology transfer agreement with Merck contributed 37.8 million USD to quarterly revenue and raised the gross margin to 64%. For the full year the company still records a net loss of 44 million USD despite the quarter’s results, expects negative EPS for 2026, and is focused on expanding the ECO-Synthesis platform and a GMP production facility by the end of 2027. » Altro su de.investing.com